摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Hydroxy-4-(1-methylethyl)-1H-pyrazole | 1211594-50-1

中文名称
——
中文别名
——
英文名称
1-Hydroxy-4-(1-methylethyl)-1H-pyrazole
英文别名
1-hydroxy-4-propan-2-ylpyrazole
1-Hydroxy-4-(1-methylethyl)-1H-pyrazole化学式
CAS
1211594-50-1
化学式
C6H10N2O
mdl
MFCD11109635
分子量
126.16
InChiKey
DPUMMZUEKGYKKY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    38
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
    申请人:Acerta Pharma B.V.
    公开号:US20170136014A1
    公开(公告)日:2017-05-18
    Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-δ inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-δ inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
  • PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION
    申请人:BioIncept, LLC
    公开号:US20170336406A1
    公开(公告)日:2017-11-23
    Embodiments are directed to methods of examining preimplantation factor (PIF) binding to a subject's circulating immune cells as a marker for immune dysregulation. Some embodiments are directed to methods of detecting a level of immune dysregulation sufficient to cause recurrent pregnancy loss (RPL), methods of detecting a level of immune dysfunction sufficient to cause endometriosis, and methods of detecting a level of immune dysfunction comprising administering an effective amount of PIF or an analog thereof, and examining its binding to circulating immune cells. Within those methods, an about twenty percent change in PIF binding to a subject's circulating immune cells indicates a level of immune dysfunction.
  • US9814722B2
    申请人:——
    公开号:US9814722B2
    公开(公告)日:2017-11-14
  • US9949971B2
    申请人:——
    公开号:US9949971B2
    公开(公告)日:2018-04-24
查看更多